A vine tea plant compound repurposed as the active ingredient in facial serums, proposed to loosen the chemical tags silencing genes in aging skin cells. Measured gains in wrinkle depth, smoothness, skin thickness and brightness were real but modest, from one short study with no comparison group, funded by the company selling it. Uncertainty here concerns attribution, not harm. (Full Review)

Protocol

Standard topical regimen

Serum twice daily

To clean, dry skin of the whole face and neck, followed each morning by factor 50 or higher sunscreen.

Competing approach, oral supplementation

300–600 mg daily

Range tested in fatty liver trials. No oral protocol has ever been tested against a skin outcome.

Best time of day

Morning and night

Oral doses with a fat-containing meal for absorption.

Time to effect

Radiance and perceived skin age

4–8 weeks

Radiance was among the fastest-moving parameters and the largest visually graded change, with expert-rated skin age falling alongside by 8 weeks.

Wrinkle visibility and roughness

4–8 weeks

Instrumental wrinkle change was already significant at 4 weeks and larger at 8.

Dermal density

4 weeks

Rose further at 8 weeks. Nothing is known beyond eight weeks.

Benefits

High: Improved liver enzymes and glucose–lipid markers with oral use

Low: Reduced wrinkle visibility and surface roughness; increased dermal density, firmness and elasticity; improved radiance and perceived skin age; reduced next-day impairment after alcohol

Speculative: Reduction in epidermal epigenetic age; suppression of melanin formation; protection from ultraviolet damage; anti-glycation and collagen preservation; fibroblast senescence modulation; suppression of inflammatory skin disease; accelerated wound healing

Contraindications

Pregnant and breastfeeding women

History of melanoma or non-melanoma skin cancer within the treatment field

Active eczema, rosacea flare or broken skin barrier in the application area, until recovered

Oral use within 14 days of surgery, injectables or needling; within 90 days of full-face resurfacing

Documented plant-compound or vine tea contact allergy

Children and adolescents under 18 years

Key Interactions

Transporter substrates (rosuvastatin, fexofenadine)

Efflux-pump inhibitors (verapamil, ketoconazole)

Cytochrome P450 substrates (midazolam, warfarin)

Benzodiazepines and non-benzodiazepine sleep medicines (diazepam, zolpidem)

Acetaminophen (paracetamol)

Alcohol

Blood-sugar-lowering medicines (metformin, insulin)

Blood thinners and antiplatelet medicines (warfarin, aspirin)

Supplements with additive blood-sugar lowering (berberine, chromium)

Supplements competing for the same clearance routes (quercetin, curcumin)

Topical retinoids (tretinoin), exfoliating acids (glycolic) and benzoyl peroxide

Procedural treatments (laser, microneedling, peel)

Risk & Side Effects

Low: Application-site irritation and contact sensitization; gastrointestinal intolerance with oral dosing

Speculative: Cancer risk from loss of DNA methylation; unintended loss of pigment; suppression of androgen signaling; reduced platelet reactivity; gut bacterial shifts with oral dosing

Monitoring

Marker	Target	Why
Epidermal DNA methylation age	No target; change from baseline, below chronological age	The measure used to claim rejuvenation
Standardized facial photography	No target; change in wrinkle and texture scores from baseline	The only endpoint reflecting what is visible
Dermal echogenicity	No target; change from baseline	Objective density measure in the deeper skin layer
Alanine aminotransferase	10–26 U/L women, 10–33 U/L men	Detects liver-cell stress during oral use
Gamma-glutamyl transferase	Below 20 U/L	Early marker of oxidative and bile-duct stress
Glycated hemoglobin	4.8–5.4%	Collagen glycation is a targeted skin-aging pathway
Fasting glucose	75–86 mg/dL	Oral dosing lowers it; additive hypoglycemia shows here first
High-sensitivity C-reactive protein	Below 0.5 mg/L	Low-grade inflammation accelerates visible skin aging
25-hydroxyvitamin D	40–60 ng/mL	Daily high-protection sunscreen reduces skin synthesis

Cadence: Photographs and instrument measures at 4 and 8 weeks, then every 3 months; liver and glucose panels at 12 weeks for oral use, then every 6–12 months.

Qualitative Assessment

Morning skin feel: tightness, roughness or comfort
Makeup behavior: whether foundation settles into lines less
Perceived radiance in daylight rather than bathroom lighting
Tolerance signals: stinging, flushing or peeling
Unprompted comments from other people, which track visible change better than self-assessment

Dihydromyricetin for Skin Rejuvenation

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment